Weight loss stock Terns Pharmaceuticals has potential with 462% price target increase, but faces competition.

From Nasdaq: 2025-03-09 10:03:00

Viking Therapeutics impressed with phase 2 results for weight loss drug, but Terns Pharmaceuticals (NASDAQ: TERN) shows even higher potential with a 462% price target increase. Terns focuses on weight loss and oncology medicines, with promising candidates TERN-601 and TERN-501. However, uncertainty surrounds Terns’ prospects, especially with competition in the market. While TERN-601 showed positive weight loss results in phase 1, Terns’ overall success remains to be seen. Investors should weigh the risks before considering Terns Pharmaceuticals as an investment opportunity. Wall Street predictions may be optimistic but warrant caution.



Read more at Nasdaq: This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street